DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
7.95
-0.28 (-3.40%)
Feb 27, 2026, 4:00 PM EST - Market closed
DiaMedica Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for DiaMedica Therapeutics stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 25. The average target predicts an increase of 94.97% from the current stock price of 7.95.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2025.
Analyst Ratings
The average analyst rating for DiaMedica Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $25 | Buy | Initiates | $25 | +214.47% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +50.94% | Aug 15, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $8 → $11 | Strong Buy | Maintains | $8 → $11 | +38.36% | Jul 18, 2025 |
| Lake Street | Lake Street | Strong Buy Maintains $11 → $14 | Strong Buy | Maintains | $11 → $14 | +76.10% | Jul 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +50.94% | Jul 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.70
from -0.60
EPS Next Year
-0.77
from -0.70
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.58 | -0.63 | ||||
| Avg | -0.70 | -0.77 | ||||
| Low | -0.73 | -0.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.